- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04752215
A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface
A First-in-human Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 765049 and BI 765049 + BI 754091 Administered by Parental Administration(s) in Patients With Malignant Solid Tumors Expressing B7-H6
This study is open to adults with advanced solid tumors whose previous cancer treatment was not successful. People can participate if their tumor has the B7-H6 marker or if they have colorectal cancer.
The study tests 2 medicines called BI 765049 and ezabenlimab (BI 754091). Both medicines may help the immune system fight cancer.
The purpose of this study is to find out the highest dose of BI 765049 alone and in combination with ezabenlimab the participants can tolerate. In this study, BI 765049 is given to people for the first time.
Participants can stay in the study for up to 3 years, if they benefit from treatment and can tolerate it. During this time, they get BI 765049 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks.
The doctors check the health of the participants and note any health problems that could have been caused by BI 765049 or ezabenlimab. The doctors also regularly monitor the size of the tumor.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Boehringer Ingelheim
- Phone Number: 1-800-243-0127
- Email: clintriage.rdg@boehringer-ingelheim.com
Study Contact Backup
- Name: additional contact: Sarah Cannon Development Innovations
- Phone Number: 844-710-6157
- Email: CANN.InnovationsMedical@sarahcannon.com
Study Locations
-
-
-
Toronto, Canada, M5G 1Z5
- Recruiting
- Princess Margaret Cancer Centre
-
Contact:
- Boehringer Ingelheim
- Phone Number: 18336022346
- Email: canada@bitrialsupport.com
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama At Birmingham
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
California
-
Los Angeles, California, United States, 90067
- Recruiting
- Valkyrie Clinical Trials
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
Orange, California, United States, 92868
- Recruiting
- University of California Irvine
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- HealthONE
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Florida
-
Sarasota, Florida, United States, 34232
- Recruiting
- Florida Cancer Specialists
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Healthcare - Norton Cancer Institute - Louisville
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
New York
-
New York, New York, United States, 10016
- Recruiting
- New York University Langone Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- Stephenson Cancer Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Recruiting
- Tennessee Oncology, PLLC
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Texas
-
Dallas, Texas, United States, 75246
- Recruiting
- Baylor University Medical Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
Dallas, Texas, United States, 75230
- Recruiting
- Mary Crowley Cancer Research Center
-
Contact:
- Boehringer Ingelheim
- Phone Number: 833-602-2368
- Email: unitedstates@bitrialsupport.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed and dated, written informed consent form (ICF) (ICF1 for B7-H6 testing for all patients except those with advanced or metastatic colorectal cancer (CRC); and ICF2 for all patients) describing the study in accordance with International Council on Harmonisation Good Clinical Practice (ICH-GCP) and local legislation prior to any trial-specific procedures, sampling, or analyses.
- Patient must be ≥18 years of age at the time of signature on the ICFs (ICF1 and ICF2).
- Patients with a histologically or cytologically confirmed diagnosis of an advanced, unresectable, and/or metastatic colorectal carcinoma (CRC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), gastric carcinoma, and pancreatic carcinoma. At least 1 patient in each back-fill slot must be a non-CRC patient (i.e., NSCLC, HCC, HNSCC, gastric carcinoma, or pancreatic carcinoma).
- Patients with disease progression despite conventional treatment, intolerant to or not a candidate for conventional treatment, or with a tumor for which no conventional treatment exists.
- All patients must agree to the collection of tumor samples (as slides from archival diagnostic samples or fresh tumor biopsies) for confirmation of B7-H6 expression either at Screening visit 02 (for CRC patients) or Screening visit 01 (for all other patients). To qualify for a back-fill slot or recommended dose expansion (RDE) cohort, the patient must agree to the collection of mandatory pre-treatment and on-treatment fresh tumor biopsies.
- Patient diagnosed with advanced or metastatic CRC or patient with confirmed B7-H6 expression on tumor tissue sample (archived or fresh tumor biopsy) based on central pathology review.
- Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Patient must have at least one evaluable target lesion outside of the central nervous system (CNS) as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 separate from any lesion(s) identified for tumor biopsy. Tumor lesions that have been irradiated at least ≥28 days before the start of treatment, and have subsequently had documented progression, may be chosen as target lesions only in the absence of measurable lesions that have not been irradiated.
- Further inclusion criteria apply
Exclusion Criteria:
- Patient with a history of a major surgery within 28 days prior to first dose of BI 765049 (major according to the Investigator's and/or Medical Monitor's assessment).
- Patient with a history of a previous or concomitant malignancies. Patient with a malignancy considered effectively treated and cured by 'local treatment' within the last 2 years and that is distinct from the one treated in this trial will be allowed.
- Patient with known leptomeningeal disease or spinal cord compression due to disease.
- Patient requiring anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the Investigator.
- History of systemic antimicrobials required for an infection within 7 days of first dose BI 765049.
Patient with any of the following laboratory evidence of hepatitis virus infection. Test results obtained in routine diagnostics are acceptable for screening if done within 14 days before the ICF2 date:
- Positive results of hepatitis B surface (HBs) antigen
- Presence of hepatitis B core (HBc) antibody together with hepatitis B virus (HBV)-DNA
- Presence of hepatitis C-RNA
- Patient with known human immunodeficiency virus (HIV) infection.
Patient previous treatment history:
- Treatment with a systemic anti-cancer therapy or investigational drug within 21 days or 5 half-lives (whichever is shorter) of the first administration of BI 765049.
- Treatment with extensive field radiotherapy including whole brain irradiation within 14 days prior to first administration of BI 765049.
- Further exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BI 765049 single treatment group
BI 765049
|
BI 765049
|
Experimental: BI 765049 + ezabenlimab combination treatment group
BI 765049 + ezabenlimab
|
ezabenlimab
BI 765049
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD) in any studied regimen
Time Frame: Up to 3 weeks
|
defined as the highest dose with less than 25 percent (%) risk of the true dose limiting toxicity (DLT) rate being equal to or above 33 percent (%) during the MTD evaluation period
|
Up to 3 weeks
|
Number of patients with dose limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
Time Frame: Up to 3 weeks
|
Up to 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum measured concentration of BI 765049 (Cmax)
Time Frame: Up to 36 months
|
Up to 36 months
|
Area under the concentration-time curve of BI 765049 over a uniform dosing interval τ (AUCτ)
Time Frame: Up to 36 months
|
Up to 36 months
|
Objective response based on Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in patients with measurable disease
Time Frame: Up to 36 months
|
Up to 36 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Gastrointestinal Diseases
- Endocrine Gland Neoplasms
- Liver Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Colonic Diseases
- Intestinal Diseases
- Liver Neoplasms
- Intestinal Neoplasms
- Rectal Diseases
- Lung Neoplasms
- Pancreatic Diseases
- Neoplasms
- Head and Neck Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Hepatocellular
- Colorectal Neoplasms
- Pancreatic Neoplasms
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
Other Study ID Numbers
- 1454-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
For more details refer to: https://www.mystudywindow.com/msw/datasharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms
-
Fusion Pharmaceuticals Inc.AstraZenecaRecruitingAdvanced Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Metastatic Colorectal CarcinomaUnited States, Canada
-
MedImmune LLCCompletedMetastatic Castration-resistant Prostate Cancer (mCRPC) | Small Cell Lung Cancer (SCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Colorectal Cancer (CRC) | Non Small Cell Lung Cancer Squamous (NSCLC-Sq)United States, Canada
-
Novartis PharmaceuticalsTerminatedColorectal Cancer | Gastrointestinal Stromal Tumors | Non-small Cell Lung Carcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal SCCUnited States, Germany, Spain, Singapore, Australia, Hong Kong, Belgium, Japan, China
-
Seagen Inc.TerminatedMelanoma | Soft Tissue Sarcoma | Colorectal Cancer | Non-small Cell Lung Carcinoma | Breast Carcinoma | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Ovarian Carcinoma | Exocrine Pancreatic CarcinomaUnited States
-
Neogene Therapeutics, Inc.RecruitingBreast Cancer | Pancreatic Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma | Other Solid TumorsUnited States
-
Regeneron PharmaceuticalsSanofiRecruitingHepatocellular Carcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell CarcinomaUnited States
-
Fate TherapeuticsCompletedMelanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | HER2-positive Breast Cancer | Head and Neck Squamous Cell Carcinoma | HER2 Positive Gastric Cancer | EGFR Positive Solid TumorUnited States
-
Seagen Inc.RecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Squamous Cell Carcinoma of the Head and Neck | Pancreatic Ductal AdenocarcinomaUnited States
-
Assistance Publique - Hôpitaux de ParisTerminatedAdvanced Head and Neck Carcinoma | Advanced Non-small Cell Lung CarcinomaFrance
-
University Health Network, TorontoAstraZenecaWithdrawnSquamous Cell Carcinoma of Head and Neck | Non-small Cell Lung Cancer | Pancreatic Ductal AdenocarcinomaCanada
Clinical Trials on ezabenlimab
-
Institut BergoniéBoehringer IngelheimNot yet recruitingColorectal Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Biliary Tract Cancer | Adult Soft Tissue SarcomaFrance
-
Boehringer IngelheimRecruitingSolid TumorsUnited States, Japan, Canada
-
Boehringer IngelheimRecruitingNeuroendocrine Neoplasms | Small Cell Lung Carcinoma (SCLC)Germany, Belgium, Japan, France
-
Boehringer IngelheimRecruitingSolid TumorsUnited States, Spain, Germany, Austria, France, Belgium
-
Boehringer IngelheimRecruitingNeoplasmsSpain, United States, Belgium, Japan, Netherlands, Italy
-
Boehringer IngelheimRecruitingHead and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Lung Cancer | Gastrointestinal Cancer | Liver CancerJapan
-
Amal TherapeuticsBoehringer IngelheimRecruitingPancreatic Ductal AdenocarcinomaUnited States, Switzerland
-
Boehringer IngelheimActive, not recruitingNeoplasms | Non-squamous, Non-Small-Cell Lung CancerUnited States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
-
Boehringer IngelheimRecruitingSolid TumorsSpain, Japan, United Kingdom, United States
-
Boehringer IngelheimCompletedNeoplasmsSpain, United States, United Kingdom